Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Annette G. Ziegler"'
Autor:
Sari Niinistö, Iris Erlund, Hye-Seung Lee, Ulla Uusitalo, Irma Salminen, Carin Andrén Aronsson, Hemang M. Parikh, Xiang Liu, Sandra Hummel, Jorma Toppari, Jin-Xiong She, Åke Lernmark, Annette G. Ziegler, Marian Rewers, Beena Akolkar, Jeffrey P. Krischer, David Galas, Siba Das, Nikita Sakhanenko, Stephen S. Rich, William Hagopian, Jill M. Norris, Suvi M. Virtanen, the TEDDY Study Group
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
Abstract Our aim was to investigate the associations between erythrocyte fatty acids and the risk of islet autoimmunity in children. The Environmental Determinants of Diabetes in the Young Study (TEDDY) is a longitudinal cohort study of children at h
Externí odkaz:
https://doaj.org/article/0fa4073057894bb298076894588d4e7e
Autor:
Naiara G. Bediaga, Alexandra L. Garnham, Gaetano Naselli, Esther Bandala-Sanchez, Natalie L. Stone, Joanna Cobb, Jessica E. Harbison, John M. Wentworth, Annette-G. Ziegler, Jennifer J. Couper, Gordon K. Smyth, Leonard C. Harrison
Publikováno v:
Diabetes
Type 1 diabetes in children is heralded by a preclinical phase defined by circulating autoantibodies to pancreatic islet antigens. How islet autoimmunity is initiated and then progresses to clinical diabetes remains poorly understood. Only one study
Autor:
Annette-G Ziegler, Johnny Ludvigsson, Mikael Knip, Jennifer J Couper, Michael J. Haller, Maria E. Craig
Publikováno v:
Pediatric Diabetes. 15:18-25
Supplement: International Society for Pediatric and Adolescent Diabetes (ISPAD) Clinical Practice Consensus Guidelines 2014. This article is a chapter in the ISPAD Clinical Practice Consensus Guidelines 2014 Compendium. The complete set of guidelines
Autor:
Jennifer J, Couper, Michael J, Haller, Annette-G, Ziegler, Mikael, Knip, Johnny, Ludvigsson, Maria E, Craig
Publikováno v:
Pediatric diabetes. 15
Autor:
Evy Vandemeulebroucke, Peppy Rebello, Ibrahim Al Bakir, William J. Jusko, E Bolam, Paweł Wiczling, Annette-G Ziegler, Chantal Mathieu, Bart Keymeulen, Geoff Hale, Lucienne Chatenoud, Herman Waldmann
Publikováno v:
Journal of clinical pharmacology. 50(11)
Otelixizumab is a chimeric CD3 antibody that has been genetically engineered to remove the glycosylation site in the Fc domain. This limits its ability to bind to complement or Fc receptors and reduces the risk of adverse clinical reactions due to cy
Publikováno v:
Diabetes care. 20(6)
OBJECTIVE To determine whether screening for the presence of multiple antibody markers for IDDM is effective at identifying individuals with high risk for disease development. RESEARCH DESIGN AND METHODS Antibodies to GAD and the tyrosine phosphatase